Antibody response to 2-dose SARS-CoV-2 mRNA vaccination in pediatric solid organ transplant recipients

Responsiveness to second and third dose of mRNA COVID‐19 vaccination in adolescent and young adult heart transplant recipients

“…In this single‐center analysis, 61% of adolescent and young adult HT recipients had detectable SARS‐CoV‐2 spike protein Ab at a median of just over 3 months from second‐dose vaccination. This is far below the >98% responsiveness seen in healthy children and adolescents in response to the mRNA vaccines, 14 , 15 but similar to data reported among adult 1 and adolescent SOT recipients 7 , 8 , 9 , 10 with Ab response after two doses of mRNA COVID‐19 vaccine. Encouragingly, we observed Ab production after third mRNA COVID‐19 vaccine dose among four of seven (57%) adolescent and young adult HT recipients who were negative after their second dose.…”

“… 1 , 2 , 3 , 4 , 5 , 6 Presently, data on responsiveness to COVID‐19 mRNA vaccination in adolescent SOT recipients consist of a handful of reports showing diminished Ab production after a two‐dose regimen among predominantly liver and renal transplant recipients (73%) relative to healthy adolescents. 7 , 8 , 9 , 10 We sought to characterize Ab production in response to COVID‐19 mRNA vaccination, including response to third‐dose vaccination, in a convenience sample of adolescent and young adult HT recipients.…”

Return to School and COVID-19 Vaccination for Pediatric Solid Organ Transplant Recipients in the United States: Expert Opinion for 2021-2022

“…Studies in pediatric SOT recipients are limited. A recent study of 57 pediatric SOT recipients found that 73% had positive antibody responses after 2 doses of mRNA vaccine [ 59 ], higher than most reports following a 2-dose series in adults. However, post-vaccine cellular immune responses, as well as the rate and severity of infection after vaccination in SOT recipients, have not yet been fully evaluated.…”

The impact of COVID-19 on the pediatric solid organ transplant population

“… 54 , 55 , 56 , 57 For transplant recipients, future studies are needed to better understand the humoral and cell-mediated response to COVID-19 vaccine, as well as the length of time that clinical protection remains, and the impact of various degrees of immunosuppression. 47 For those recipients who acquired COVID-19 disease, there is much to learn about optimal therapy and the long-term medical sequelae. Finally, across the entire pediatric population there has been a significant rise in mental health challenges during the COVID-19 pandemic.…”

“…In this cohort, none of the vaccinated children experienced any serious adverse events including allergic reaction, myocarditis, new neurologic condition, organ rejection or death. 47 Early data suggests an additional immune benefit of a third vaccine dose in pediatric solid organ transplant recipients. In a study of 43 patients who received three BNT162b2 doses, 88% had positive antibodies one month after the third COVID-19 vaccine dose.…”